Cavernous Hemangioma clinical trials at UCSF

2 in progress, 1 open to eligible people

Cavernous hemangiomas are abnormal clusters of blood vessels in the brain and spine. UCSF is studying how these clusters can cause strokes and seizures. The trials are looking at what makes the disease worse.

Showing trials for

  • Modifiers of Disease Severity in Cerebral Cavernous Malformations

    open to all eligible people

    Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3). There is a wide range of disease severity even among family members with this disease, though the natural history has not been clearly described for this particular population. This study will continue to enroll and follow participants with familial CCM to identify factors that influence CCM disease severity and progression, focusing on barriers to clinical trial preparedness. Our long-term goal is to identify measurable outcomes and robust biomarkers that will help select high-risk patients and help monitor drug response in future clinical trials. The specific goals of this study are to: - Identify factors that influence lesion progression to symptomatic hemorrhage and other outcomes, including quality of life; - Investigate the role of the gut microbiome and lesion burden in CCM disease, and - Identify blood biomarkers predictive of CCM disease severity and progression for clinical trials.

    San Francisco, California and other locations

  • Biomarkers of CASH

    Sorry, not currently recruiting here

    The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

    San Francisco, California and other locations

Our lead scientists for Cavernous Hemangioma research studies include .

Last updated: